Medindia

X

Bioponic Phytoceuticals Appoints Renowned Physician Dr. Barbara Nabrit-Stephens to Scientific Advisory Board

Wednesday, April 23, 2008 General News J E 4
Advertisement
KULA, MAUI, Hawaii, April 22 BioponicPhytoceuticals, Inc. (OTC Bulletin Board: BPYT) ("Bioponic" or "the Company")today announced that Dr. Barbara Anne Nabrit-Stephens, MD, MBA, FAAP hasjoined the Company's Scientific Advisory Board. Dr. Nabrit-Stephens is aboard-certified pediatrician with over 30 years of health care experience. Asa scientific advisor, Dr. Nabrit-Stephens will help validate and formulateBioponic's strategies to market its all-natural therapeutic products,including Curecumin(TM) and Curmisinin(TM).

"We are honored to welcome Dr. Nabrit-Stephens to our Scientific AdvisoryBoard. Dr. Nabrit-Stephens' in-depth experience as both a clinician and healthcare administrator is a true asset to our organization," said Steven M.Schorr, Chairman and CEO of Bioponic. "Testing and research programs forAlzheimer's applications for Curecumin(TM) and distribution of Curmisinin(TM)to treat the deadly cerebra malaria, which kills over 2 million children inSub-Saharan Africa, are the first projects Dr. Nabrit-Stephens will beinvolved in. She is also ideally suited to advise us on our newest productline, Gentle Mother, specifically for the needs of newborns and infants."

Dr. Nabrit-Stephens said, "I've always been attracted to those companieswho focus on providing pro-active healthcare solutions, especially to thosepopulations at-risk. Bioponic's work in bringing all-natural treatments tocontrol devastating malaria in Africa is very impressive. I believe Bioponic'sBioresonant formulations could potentially represent a breakthrough in thetreatment of epidemic disease. I am intrigued to discover more about theCompany and their product lines, and look forward to our ongoingcollaboration."

Dr. Nabrit-Stephens earned her medical degree from Tufts University in1976, her BA from Harvard University in 1972, and her MBA from the Universityof Tennessee in 1998. She served as a private pediatrician for years inNashville, Tennessee, before she joined the health-care administrationindustry in the late 1990s. Dr. Nabrit Stephens is currently Medical Directorof Care Management at Blue Cross Blue Shield of Florida in Tampa. Prior tojoining BC/BS in 2006, Dr. Nabrit-Stephens was Vice President, Medical Affairsat Keystone Mercy Health, Southeastern Pennsylvania's largest medicalassistance managed health care plan organization from 2003 to 2005. Herprevious administrative professional positions include Medical Director atOmniCare Health Plan and Plan Medical Director at Tennessee Managed CareNetwork.

Dr. Nabrit-Stephens also has a wealth of experience in academia. She hasserved as an assistant professor, director of education for the Department ofPediatrics, Meharry Medical College, and an assistant clinical professor atthe Vanderbilt University School of Medicine. In addition, she has done variedresearch, particularly in the area of HIV/AIDS, where she worked with pregnantwomen who were HIV-positive and transmitting the virus from mother to baby.

About Bioponic Phytoceuticals

Bioponic Phytoceuticals is engaged in the development, production anddistribution of Bioresonant Phytotherapeutic(TM) products. The Company hasdeveloped several branded product lines (including the nasal spray: FlightSpray(R) (http://www.flightspray.com) and the skincare product HawaiianHealing Mist(TM)). Bioponic is focused on the production of natural productsthat are used to promote health and well-being. Visit http://www.bioponic.com.

All statements other than statements of historical fact included in thispress release are "forward-looking statements" within the meaning of federalsecurities laws. Such forward-looking statements are subject to a number ofrisks and uncertainties, some of which are beyond the Company's control.

CONTACT: Steven M. Schorr, CEO, Bioponic Phytoceuticals, +1-808-876-1711,info@bioponic.com or Rick McCaffrey, Investor Rela
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Genzyme to Build New R&D Center in Beijing
S
Glass Lewis & Co. Recommends Renovis Shareholders ...